Cash-flush Novartis launches new share buyback of up to $15 bn

The buyback is funded through the $20.7 billion the Swiss drugmaker raised by selling its nearly one-third voting stake in Roche back to its cross-town rival last month

Powered by WPeMatico

Scroll to top